Perioperaciina Medicina 2021-03-11T19:22:10+02:00 Oleksandr Marchuk Open Journal Systems Efficacy comparative characteristics of antiseptic DECASAN Yuria-Pharm and CUTASEPT G in the treatment of purulent inflammatory diseases of various localization 2021-03-11T18:35:58+02:00 V N Lykhman S V Tkach <p><strong>Background:</strong> High mortality because of various infectious complications (immediate cause in 42.5 % of cases), the ever-increasing frequency of purulent inflammatory diseases, as well as the growth of microbial resistance to anti-bacterial drugs, force to seek a solution to the problem among local antiseptics. <br><strong>Aim:&nbsp;</strong>to compare the effectiveness of antiseptics DECASAN Yuria-Pharm and CUTASEPT G in the treatment of puru-lent inflammatory diseases of different localization.<br><strong>Materials&nbsp;and&nbsp;methods:</strong> The study involved 30 patients with purulent inflammatory diseases of various localiza-tions. Patients were divided into two groups, according to the chosen tactics of local antiseptic therapy, in patients of the first study group (n = 15; mean age – 49.73 ± 6.35 years) antiseptic treatment was performed with a drug based on 0.02 % decamethoxine (Decasan). In the second group (n = 15; mean age – 51.4 ± 5.14 years) treatment was performed with a disinfectant (skin antiseptic) “Cutasept G”. Collection of material for microbiological examination (bacteriological culture) was performed before treatment, 3 and 5 days after treatment. Probability analysis was performed according to Student’s t-test. A statistically significant difference between the indicators was considered when the probability of validity of the null hypothesis was less than 5 % (p &lt;0.05).<br><strong>Results:</strong> Analyzing the results of bacteriological examination of both groups, in the first, where Decasan was used and in the second, with the use of Cutasept G, it was found that at the beginning of treatment there was a pronounced microbial colonization of wounds, not significantly different among patients in both groups (p &lt;0.05). Microbio-logical observation of the course of purulent-inflammatory process in the dynamics showed a significantly slowed down process of microbial purification in the second group (Cutasept G), the condition for 5 days was lg (8.8 ± 0.4) CFU/ml. At that time for patients of the first comparison group the number of microorganisms in 1 ml of wound contents, expressed in lg, was (4.8 ± 0.4) CFU/ml, which does not exceed the critical level. The obtained values were significantly higher than with Cutasept G (p &lt;0.05), which was twice higher than the level of microbial colonization compared to the treatment of wounds with 0.02 % decamethoxine solution (p &lt;0.001).<br><strong>Conclusions:</strong> The use of antiseptic 0.02 % decamethoxine for 5 days provides a reduction in the number of oppor-tunistic pathogens lg (4.8 ± 0.4) CFU/ml, which is 1.9 times lower (p &lt;0.05) compared with the use of Cutasept G, creating conditions for the settlement of normal microbiotic skin (Corynebacterium spp., S. epidermidis). Antiseptic Dekasan is characterized by good healing properties due to its high antimicrobial activity, isotonicity, which makes it possible to use it successfully in patients with purulent inflammatory diseases of various localizations. In addition, the use of Dekasan promotes rapid cleansing of wounds from purulent-necrotic contents and formation of granula-tion tissue in them.</p> 2021-03-11T00:00:00+02:00 Copyright (c) 2021 Use of Linezolid in the treatment of surgical infectious complications under antibiotic resistance 2021-03-11T19:13:25+02:00 O A Nazarchuk V L Vitkovskiy Yu M Babina <p>Linezolid – a first representative of the new class of synthetic antibiotics oxazolidones. Its antibacterial spectrum includes Gram-positive microorganisms, including multi-resistant strains. Its unique mechanism of action conditions absence of cross-resistance with other antibiotics. This drug is presented in peroral and parenteral forms. Unlike vancomycin, it has optimal pharmacokinetic profile. Linezolid was approved by Food and Drug Administration (FDA) in 2000 for the treatment of the following diseases: hospital- and community-acquired pneumonia, skin and soft tissue infections with or without complications caused by Gram-positive bacteria, vancomycin-resistant enterococci and pneumococcal meningitis, caused by penicillin-resistant Streptococcus pneumoniae.</p> 2021-03-11T00:00:00+02:00 Copyright (c) 2021 Role and place of levofloxacin in the treatment of community-acquired pneumonia 2021-03-11T19:22:10+02:00 D V Dmytriiev O A Nazarchuk Yu M Babina <p>Lower respiratory tract infections are the third mortality cause in the world and the first mortality cause in low-income countries. Community-acquired pneumonia (CAP) is a dangerous infectious pathology, especially in children younger than 5 years, elderly people and patients with compromised immunity. Antibiotic therapy is a standard treatment method for CAP. But an increase in antibiotics use caused a development of resistance in bacteria and onset of adverse events in humans. A new class of fluorchinolones is widely used nowadays in clinical practice. They have good activity against Gram-negative bacteria, as early chinolones, as well as against Gram-positive bacteria, such as pneumococci and atypical bacteria. An increasing amount of penicillin-resistant streptococcal pneumonia leads to more intensive studies of the use of new chinolones. In this review the data of 750 mg levofloxacin is presented. It is used in short courses for the treatment of severe and moderate CAP. Taking into account the broad spectrum of activity of levofloxacin ad bactericidal activity of this antibiotic, it can be a potential alternative therapy for the treatment of children and adults with CAP, especially with a tendency of an increase in antibiotic resistance of pneumococcus.</p> 2021-03-11T00:00:00+02:00 Copyright (c) 2021 Tobramycin: efficacy of intensive therapy 2021-03-11T17:39:37+02:00 D V Dmytriiev O A Nazarchuk Yu M Babina O V Bankovskiy <p>One of the leading cause of the decrease of treatment efficacy in patient with community-acquired infections in the intensive care department is a spread of antibiotic resistance in main causative agents. Among Gram-negative microorganisms Pseudomonas aeruginosa is one of the leading causative agents, that is related to health service. A review of foreign and domestic literature concerning tobramycin – systemic form use in the current medical practice in the conditions of increasing resistance of microorganisms to the most broad-spectrum antibiotics is presented in the article. Pharmacokinetic and pharmacodynamic characteristics of tobramycin are described, results of clinical trials, that demonstrate an efficacy of its use in the combination with other antibiotics in the life-threatening infections caused by Gram-negative microorganisms are presented in the article.</p> 2021-03-11T00:00:00+02:00 Copyright (c) 2021 Levofloxacin efficacy in current surgical practice 2021-03-11T18:09:03+02:00 O A Nazarchuk Yu M Babina D V Dmytriiev V L Vitkovskiy <p>Results of domestic and international studies of the 3rd generation fluorchinolone Levofloxacin use in the prevention and treatment of inflammative diseases of the skin, soft tissues, intrabdominal and urogenital infectious complications is presented in the article. Analysis of clinical use of Levofloxacin in the treatment of many diseases indicates its high efficacy, absence of complications, low risk of resistance development, that allows to recommend it for the wide use in in medical practice.</p> 2021-03-11T00:00:00+02:00 Copyright (c) 2021 Use of ornidazole in the treatment of anaerobic infection in surgery 2021-03-11T18:23:58+02:00 Yu M Babina O A Nazarchuk D V Dmytriiev <p>One of the most complex problems of modern surgery is the treatment and prevention of anaerobic infection. Main place in overcoming of this infectious complication is devoted to urgent surgical intervention and correct early empiric antibacterial therapy. Special place in the combined empiric antibacterial treatment is devoted to 5-nitroimidazoles. Modern data about clinical efficacy of ornidazole in the treatment of surgical infectious complications is presented in the article. We performed a comparison of therapeutic activity and physical-chemical properties, pharmacokinetic and pharmacodynamic features of ornidazole with the first representative of 5-nitroimidazole class – metronidazole. Taking into account antiprotozoal and antianaerobic activity of ornidazole, it is recommended to be used in the schemes of combined therapy of severe generalized anaerobic infections and purulent processes of different localization; treatment and prevention of surgical infections after intraabdominal, thoracic, proctological and dental surgical interventions.</p> 2021-03-11T00:00:00+02:00 Copyright (c) 2021